Study of experimental monoclonal antibodies in Advanced Cancers

Experimental medicine as a monotherapy or in combination

Open to people ages 18 years and up

• Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. These patients do not require measurable disease
• Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Adequate organ and bone marrow function

• Prior treatment with any LAG-3 targeting biologic or small molecule
• Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation
• Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease
• Corticosteroid therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug
• Myocardial infarction within 6 months

Note: Other protocol defined Inclusion / Exclusion criteria apply